摘要
目的:探讨晚期非小细胞肺癌(NSCLC)患者基线BMI与免疫检查点抑制剂(ICI)疗效及安全性的关系。方法:回顾性分析2019年1月至2021年5月接受基于ICI治疗的晚期NSCLC患者193例的临床资料。根据免疫治疗前BMI,将患者分为超重/肥胖组(BMI≥25.0 kg/m^(2))和非超重组(BMI<25.0 kg/m^(2))。比较两组的客观缓解率(ORR)、疾病控制率(DCR)以及免疫相关不良事件(irAE)发生情况。Kaplan-Meier法绘制生存曲线,采用Log-rank检验比较两组无进展生存(PFS)和总生存(OS)生存曲线的差异。应用Cox回归分析OS的影响因素。结果:超重/肥胖组DCR高于非超重组(87.5%vs 73.6%,P=0.028)。两组任意级别irAE发生率(29.7%vs 34.1%)和G3/G4 irAE发生率(4.7%vs 10.1%)比较差异均无统计学意义(P>0.05)。超重/肥胖组和非超重组OS生存曲线的差异有统计学意义(P=0.024)。Cox回归分析结果显示基线BMI是OS的影响因素(HR=0.557,95%CI为0.329~0.944)。结论:基线BMI与ICI治疗晚期NSCLC的疗效有关,BMI≥25.0 kg/m^(2)的患者DCR更高,存活时间更长。
Aim:To explore the association between baseline BMI and the efficacy and safety of immune checkpoint inhibitor(ICI)in patients with advanced non-small cell lung cancer(NSCLC).Methods:Clinical data of 193 patients with advanced NSCLC who received ICI based treatment in our hospital from January 2019 to may 2021 were retrospectively analyzed.The patients were allocated into overweight/obesity(BMI≥25.0 kg/m^(2))and non-overweight(BMI<25.0 kg/m^(2))groups according to pre-immunotherapy BMI.The objective response rate(ORR),disease control rate(DCR)and the occurrence of immune-related Adverse Event(irAE)of the 2 groups were compared.The survival curves were plotted using the Kaplan-Meier method,and Log-rank test was used to compare differences in survival curves of progression free survival(PFS)and overall survival(OS).Factors affecting OS were identified using Cox regression analysis.Results:The DCR in the overweight/obesity group was higher than that in the non-overweight group(87.5%vs 73.6%,P=0.028).No significant differences were observed between the 2 groups in either the rate of any grade irAE(29.7%vs 34.1%)or the rate of G3/G4 irAE(4.7%vs 10.1%)(P>0.05).Survival curves for OS showed a significant difference between the 2 groups(P=0.024).Cox regression analysis indicated that baseline BMI was a factor affecting OS(HR=0.557,95%CI was 0.329-0.944).Conclusion:Baseline BMI is correlated with the efficacy of ICI in patients with advanced NSCLC who received ICI treatment.Patients with BMI≥25.0 kg/m^(2) may have higher DCR and longer survival time.
作者
闫焱
焦碧航
周昆
高群
陈新峰
岳冬丽
张丽敏
YAN Yan;JIAO Bihang;ZHOU Kun;GAO Qun;CHEN Xinfeng;YUE Dongli;ZHANG Limin(Department of Oncology,the First Affiliated Hospital,Zhengzhou University,Zhengzhou 450052;Department of Thoracic Surgery,the First Affiliated Hospital,Zhengzhou University,Zhengzhou 450052;Department of Biotherapy Center,the First Affiliated Hospital,Zhengzhou University,Zhengzhou 450052)
出处
《郑州大学学报（医学版）》
CAS
北大核心
2023年第3期373-377,共5页
Journal of Zhengzhou University(Medical Sciences)
基金
国家自然科学基金青年基金项目(81902924)
河南省高等学校重点科研项目(20A320065)。
关键词
非小细胞肺癌
BMI
免疫检查点抑制剂
疗效
non-small cell lung cancer
body mass index
immune checkpoint inhibitor
efficacy
